CBPO [China Biologic Products] 8-K:
[]
CBPO [China Biologic Products] 424B7: (Original Filing)
[Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued March 2, 2016 (To Prospectus dated June 5, 2015) ,870,000 Shares 3 China Biologic Products, Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 3,870,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common stock is listed on]
CBPO [China Biologic Products] 424B7: Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued March 2,
[Registration No. 333-204761 PROSPECTUS SUPPLEMENT Issued March 2, 2016 (To Prospectus dated June 5, 2015) ,870,000 Shares 3 China Biologic Products, Inc. Common Stock The selling stockholders identified in this prospectus supplement are offering 3,870,000 shares of common stock. We will not receive any proceeds from the sale of shares by the selling stockholders. Our common stock is listed on]
CBPO [China Biologic Products] 8-K: (Original Filing)
[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT March 1, 2016 March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares Common Stock] [Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,870,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) AMENDED AND RESTATED UNDERWRITING AGREEMENT March 2, 2016 March 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule] [4 March China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Selling Stockholders Shares Underwriting Agreement We understand that 3,870,000 shares of Common Stock are to be sold by certain stockholders] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – March 1, 2016 The shares to be sold in this offering represent approximately 13.2 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] [China Biologic Announces Pricing of Secondary Offering of Common Stock BEIJING, China – March 2, 2016 China Biologic will not sell any shares of common stock in the offering and will not receive any proceeds from the sale of the Purchased Shares or the Additional Shares. prospectus@morganstanley.com This press release shall not constitute an offer to sell or the solicitation] []
CBPO [China Biologic Products] 8-K: Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES
[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT March 1, 2016 March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares Common Stock] [Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,870,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) AMENDED AND RESTATED UNDERWRITING AGREEMENT March 2, 2016 March 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule] [4 March China Biologic Products, Inc. Re: Registration Statement on Form S-3 Ladies and Gentlemen: Registration Statement Company Commission Act We have examined the registration statement on Form S-3 (No. 333-204761) (the “ Common Stock Preferred Stock Prospectus Prospectus Supplement Selling Stockholders Shares Underwriting Agreement We understand that 3,870,000 shares of Common Stock are to be sold by certain stockholders] [China Biologic Announces Secondary Offering of Common Stock BEIJING, China – March 1, 2016 The shares to be sold in this offering represent approximately 13.2 percent of the Company’s current outstanding shares of common stock. Morgan Stanley & Co. International plc is acting as the sole underwriter for the offering. prospectus@morganstanley.com This press release shall not constitute an offer to] [China Biologic Announces Pricing of Secondary Offering of Common Stock BEIJING, China – March 2, 2016 China Biologic will not sell any shares of common stock in the offering and will not receive any proceeds from the sale of the Purchased Shares or the Additional Shares. prospectus@morganstanley.com This press release shall not constitute an offer to sell or the solicitation] []
CBPO [China Biologic Products] SC 13D/A: (Original Filing)
[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT March 1, 2016 March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares] [Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,870,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) AMENDED AND RESTATED UNDERWRITING AGREEMENT March 2, 2016 March 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule] [LOCK-UP LETTER March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom As the sole underwriter named in the Underwriting Agreement (as defined below) Ladies and Gentlemen: Underwriting Agreement Company Selling Stockholders Public Offering Underwriter Shares Common Stock Restricted Period Prospectus Exchange Act Covered Securities Options provided provided i ii provided] [LOCK-UP LETTER March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom As the sole underwriter named in the Underwriting Agreement (as defined below) Ladies and Gentlemen: Underwriting Agreement Company Selling Stockholders Public Offering Underwriter Shares Common Stock Restricted Period Prospectus Exchange Act Covered Securities Options provided provided i ii provided] [LOCK-UP LETTER March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom As the sole underwriter named in the Underwriting Agreement (as defined below) Ladies and Gentlemen: Underwriting Agreement Company Selling Stockholders Public Offering Underwriter Shares Common Stock Restricted Period Prospectus Exchange Act Covered Securities Options provided provided i ii provided] [CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨ 6. Citizenship or place of organization Delaware]
CBPO [China Biologic Products] SC 13D/A: Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES
[Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,500,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) UNDERWRITING AGREEMENT March 1, 2016 March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule I Underwriter Shares] [Execution Version CHINA BIOLOGIC PRODUCTS, INC. 3,870,000 SHARES OF COMMON STOCK (PAR VALUE $0.0001 PER SHARE) AMENDED AND RESTATED UNDERWRITING AGREEMENT March 2, 2016 March 2, 2016 Morgan Stanley & Co. International plc 25 Cabot Square, Canary Wharf London, E14 4QA United Kingdom Schedule I As the Sole Underwriter named in Ladies and Gentlemen: Selling Stockholders Company Schedule II Schedule] [LOCK-UP LETTER March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom As the sole underwriter named in the Underwriting Agreement (as defined below) Ladies and Gentlemen: Underwriting Agreement Company Selling Stockholders Public Offering Underwriter Shares Common Stock Restricted Period Prospectus Exchange Act Covered Securities Options provided provided i ii provided] [LOCK-UP LETTER March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom As the sole underwriter named in the Underwriting Agreement (as defined below) Ladies and Gentlemen: Underwriting Agreement Company Selling Stockholders Public Offering Underwriter Shares Common Stock Restricted Period Prospectus Exchange Act Covered Securities Options provided provided i ii provided] [LOCK-UP LETTER March 1, 2016 Morgan Stanley & Co. International plc 25 Cabot Squire, Canary Wharf London, E14 4QA United Kingdom As the sole underwriter named in the Underwriting Agreement (as defined below) Ladies and Gentlemen: Underwriting Agreement Company Selling Stockholders Public Offering Underwriter Shares Common Stock Restricted Period Prospectus Exchange Act Covered Securities Options provided provided i ii provided] [CUSIP No. 16938C106 1. Names of reporting persons. WP X Biologics LLC 2. Check the appropriate box if a member of a group (see instructions). ¨ x (a) 3. SEC use only 4. Source of funds (see instructions) N/A 5. ¨ 6. Citizenship or place of organization Delaware]
CBPO [China Biologic Products] FWP: (Original Filing)
[Issuer Free Writing Prospectus dated March 2, 2016 Relating to Preliminary Prospectus Supplements dated March 1, 2016 to Prospectus dated June 5, 2015 Registration No. 333-204761 Unless the context requires otherwise, the words “we” and “our” refer to China Biologic Products, Inc. The following information updates the information contained in our preliminary prospectus supplement dated March 1, 2016. In the]
CBPO [China Biologic Products] FWP: Issuer Free Writing Prospectus dated March 2, 2016
[Issuer Free Writing Prospectus dated March 2, 2016 Relating to Preliminary Prospectus Supplements dated March 1, 2016 to Prospectus dated June 5, 2015 Registration No. 333-204761 Unless the context requires otherwise, the words “we” and “our” refer to China Biologic Products, Inc. The following information updates the information contained in our preliminary prospectus supplement dated March 1, 2016. In the]
